LYCOS RETRIEVER 
Einstein: Albert Einstein College
built 619 days ago
Pain Therapeutics' two lead drug candidates, MorViva(TM) and OxyTrex(TM), along with the rest of its pipeline, use proprietary technology exclusively licensed from the Albert Einstein College of Medicine. This technology combines an opioid agonist, such as morphine, with a low-dose opioid antagonist, such as naltrexone. Published results demonstrate that at extremely low doses, opioid antagonists can improve the performance of the agonist.
Source:
This sentiment was echoed by two internationally recognized diabetes experts and Isis collaborators, Dr. Gerald Shulman from Yale University and Dr. Luciano Rossetti from the Albert Einstein College of Medicine, Bronx, New York. "Using Isis' potent antisense inhibitors, we were able to investigate the role of several molecular targets in animal models of diabetes and we identified a critical target that results in the inability of insulin to inhibit excessive glucose release by the liver in obese and insulin resistant rodents," said Dr. Luciano Rossetti, M.D., Professor of Medicine and Molecular Pharmacology and Director, Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY. "The Isis antisense inhibitors reduced the expression of this gene in the liver and completely restored normal hepatic insulin action."
Source:
Born in New York City, Dr. Fleischman graduated from the City College of New York and earned his medical degree from the Albert Einstein College of Medicine. He continued his education in pediatrics at the Johns Hopkins Hospital, and completed a fellowship in perinatal physiology at the National Institutes of Health and through a Royal Society of Medicine Scholarship at Oxford University.
Source:
MORE ABOUT
Albert Einstein College